ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 237

Characterization of Peripheral Lymphocyte Phenotype in Patients with IgG4-Related Disease

Satoshi Kubo1, Shingo Nakayamada2, Maiko Yoshikawa1, Yusuke Miyazaki1, Jidong Zhao1, Ippei Miyagawa3, Shigeru Iwata4, Shintaro Hirata1, Kazuhisa Nakano3, Kazuyoshi Saito3 and Yoshiya Tanaka5, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 3University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 4First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 5University of Occupational and Environmental Health, Kitakyushu, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: IgG4 Related Disease and flow cytometry

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Miscellaneous Rheumatic and Inflammatory Diseases - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

IgG4 related disease (IgG4-RD) is a systemic disease that is characterized by the infiltration of IgG4secreting plasma cells and effector T cells into various organs. However, the characteristics and pathological role of immune cell subsets remain unclear. The aim of this study was to investigate the characteristic phenotype of immune cell subsets in IgG4-RD.

Methods:

Peripheral blood mononuclear cells were obtained from 16 patients with IgG4-RD, 4 with primary Sjogren syndrome (pSS) and 23 healthy donors (HD). The phenotype of circulating B cells, T cells were defined based on comprehensive flow cytometric analysis for human immune system termed ‘the Human Immunology Project’ by NIH/FOCIS. CD4+Bcl-6+ T follicular helper (Tfh) cells were detected by immunohistochemistry in salivary glands obtained by the biopsy.

Results:

Baseline characteristics of patients with IgG4-RD were (means); age 60 years old, symptom duration 19 months, serum IgG 2735 mg/dl, IgG4 694 mg/dl, CRP 0.7 mg/dl. The proportions of CD3+CD4+CD45RA–CCR7– effector memory T cells, CD3+CD4+CD45RA+CCR7– effector T helper cells increased, whereas naive T cells decreased in IgG4-RD, compared to HD and pSS. There was no difference in the proportion of well known helper T cell subsets (Th1, Th17, and Treg) between IgG4-RD, pSS and HD. On the other hand, the proportions of CD4+CXCR5+ICOS+ Tfh and CD19+CD20–CD27+CD38+ plasmablasts were significant higher in IgG4-RD, compared to pSS and HD. Moreover, the proportion of Tfh in peripheral blood tended to be higher in patients whose Tfh more densely accumulated in the salivary gland. Among multiple immune cell subsets, the proportion of Tfh and that of plasmablasts were positively correlated, revealing statistical clustering. Of note, the percentage of plasmablasts was correlated with serum IgG levels. Furthermore, the proportion of plasmablasts and that of Tfh were higher in patients with extra glandular manifestations, compared to patients without them. After treatment with glucocorticoids, the proportion of plasmablasts and that of Tfh decreased with the improvement of clinical manifestations.

Conclusion: These results revealed that the higher proportion of Tfh cells and plasmablasts is characteristically observed in IgG4-RD. The frequency of Tfh was correlated with that of plasmablasts, and the Tfh/plasmablast axis contributed to organ manifestation of IgG4-RD. Our findings would clarify the pathogenesis of IgG4-RD through the interaction between Tfh cells and plasmablasts and suggest a potential as the therapeutic target of this disease.


Disclosure: S. Kubo, Bristol-Myers Squibb, 5; S. Nakayamada, None; M. Yoshikawa, None; Y. Miyazaki, None; J. Zhao, None; I. Miyagawa, None; S. Iwata, None; S. Hirata, None; K. Nakano, None; K. Saito, None; Y. Tanaka, Bristol-Myers Squibb, MSD, Chugai, Mitsubishi-Tanabe, Astellas, AbbVie, Daiichi-Sankyo, 2,UCB Pharma, Mitsubishi-Tanabe, Abbott, AbbVie, Eisai, Chugai, Janssen, Pfizer, Takeda, Astellas, Daiichi-Sankyo, GlaxoSmithKline, AstraZeneca, Eli Lilly, Quintiles, MSD, Asahi Kasei, 5.

To cite this abstract in AMA style:

Kubo S, Nakayamada S, Yoshikawa M, Miyazaki Y, Zhao J, Miyagawa I, Iwata S, Hirata S, Nakano K, Saito K, Tanaka Y. Characterization of Peripheral Lymphocyte Phenotype in Patients with IgG4-Related Disease [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/characterization-of-peripheral-lymphocyte-phenotype-in-patients-with-igg4-related-disease/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterization-of-peripheral-lymphocyte-phenotype-in-patients-with-igg4-related-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology